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Opportunistic diagnosis of osteoporosis, 
fragile bone strength and vertebral 
fractures from routine CT scans; a review of 
approved technology systems and pathways 
to implementation
Veena Aggarwal* , Christina Maslen*, Richard L. Abel, Pinaki Bhattacharya,  
Paul A Bromiley, Emma M. Clark, Juliet E. Compston, Nicola Crabtree,  
Jennifer S. Gregory , Eleni P. Kariki, Nicholas C. Harvey, Kate A. Ward  
and Kenneth E. S. Poole  and On behalf of the Technology Working Group of the  
Osteoporosis and Bone Research Academy, Royal Osteoporosis Society
Abstract: Osteoporosis causes bones to become weak, porous and fracture more easily. 
While a vertebral fracture is the archetypal fracture of osteoporosis, it is also the most 
difficult to diagnose clinically. Patients often suffer further spine or other fractures, 
deformity, height loss and pain before diagnosis. There were an estimated 520,000 fragility 
fractures in the United Kingdom (UK) in 2017 (costing £4.5 billion), a figure set to increase 
30% by 2030. One way to improve both vertebral fracture identification and the diagnosis 
of osteoporosis is to assess a patient’s spine or hips during routine computed tomography 
(CT) scans. Patients attend routine CT for diagnosis and monitoring of various medical 
conditions, but the skeleton can be overlooked as radiologists concentrate on the primary 
reason for scanning. More than half a million CT scans done each year in the National 
Health Service (NHS) could potentially be screened for osteoporosis (increasing 5% 
annually). If CT-based screening became embedded in practice, then the technique could 
have a positive clinical impact in the identification of fragility fracture and/or low bone 
density. Several companies have developed software methods to diagnose osteoporosis/
fragile bone strength and/or identify vertebral fractures in CT datasets, using various 
methods that include image processing, computational modelling, artificial intelligence 
and biomechanical engineering concepts. Technology to evaluate Hounsfield units is used 
to calculate bone density, but not necessarily bone strength. In this rapid evidence review, 
we summarise the current literature underpinning approved technologies for opportunistic 
screening of routine CT images to identify fractures, bone density or strength information. 
We highlight how other new software technologies have become embedded in NHS 
clinical practice (having overcome barriers to implementation) and highlight how the novel 
osteoporosis technologies could follow suit. We define the key unanswered questions where 
further research is needed to enable the adoption of these technologies for maximal patient 
benefit.
Keywords: artificial intelligence, computed tomography, epidemiology, fragility fracture, 
innovation, Osteoporosis, QCT, screening, technology, vertebral fracture
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Introduction
With modern computed tomography (CT) scans, 
some portion of the patients’ spine is visualised in 
detail during ordinary chest, abdomen and pelvis 
scanning, giving ample opportunity for diagnos-
ing osteoporosis and for various methods of verte-
bral fracture assessment (VFA) technologies. 
These range from manual identification right 
through to semi-automated and fully automated 
methods, some of which are accepted for diagno-
sis by international specialist societies. A sum-
mary of products and services available to measure 
bone health in the CT-attending population is 
provided in Figure 1, highlighting the niches they 
occupy in typical primary and secondary osteopo-
rosis screening strategies. This review focus not 
only on the technologies, but also on the barriers 
to their adoption.
Artificial intelligence (AI), along with its sub-dis-
ciplines of machine learning (ML) and deep 
learning (DL) are emerging as key technologies 
with the potential to improve patient outcomes. 
ML is a set of software algorithms and statistical 
models used to perform a specific task, without 
using explicit instructions. This approach is dif-
ferent from the other types of software we review, 
where products have emerged from coding done 
intentionally (based on what developers already 
know about proven osteoporosis predictors). 
With AI, large data sets of CT images are coupled 
with knowledge of eventual fracture outcomes 
and prevalence to ‘learn’ which imaging features 
predict the outcome of interest.
This Rapid Review aims to provide a comprehen-
sive review of the topic but is not a full systematic 
review of all related literature. Cochrane guidance 
on Rapid Review methodology was published 
recently (https://tinyurl.com/y6ce5g4v). For in-
depth evaluation of the technical CT methodolo-
gies, we recommend two recent review papers.1,2
Figure 1. Comparison of available products and services (i–vi) to measure bone health in the CT-attending population, their place in 
screening and the barriers to adoption in a health service (dashed grey horizontal lines). A large proportion of older patients have previously 
undiagnosed osteoporosis (left panel), and some even have previously undiagnosed vertebral fractures (with or without osteoporosis). 
Starting with all older patients attending for routine CT, there are tools to screen all scans (Optasia ASPIRE and Zebra AI1) to identify 
possible vertebral fractures. Other tools (Mindways QCT Pro and VirtuOst) are best suited to some form of fracture risk assessment, with 
higher-risk individual scans being selected for analysis of density, strength and vertebral fracture (depending on the system).
CT, computed tomography; DXA, dual energy X-ray absorptiometry; GP, general practitioner; FEA, finite element analysis; FLS, fracture liaison 
service; FRAX, fracture risk assessment tool; QCT, quantitative CT.
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Definitions and searches for the rapid 
evidence review
Definition of ‘approved’ software and services
This review considers all technologies that have 
either received United States (US) Food and 
Drug Administration (FDA) approval, ISO 
13485 certification (in the case of Medical 
Devices that involve a phantom), a European CE 
mark for diagnosis, or are National Health Service 
(NHS) Care Quality Commission (CQC) regu-
lated technology services. We also evaluated stud-
ies showing the cost effectiveness of the use of CT 
technologies. We consider each technology, its 
mechanism, integration within clinical systems 
and the evidence for its efficacy.
Patient and public involvement
The Patient and Public team of the Royal 
Osteoporosis Society conducted a survey of mem-
bers seeking their views on different research 
questions through their Bone Academy Patient 
Insight Group (December 2019–January 2020). 
In total, 2313 patient responders with osteoporo-
sis (from 7237 mailed) graded priorities and 
expectations from 13 key areas across the domains 
of Osteoporosis Causes, Technology and Service 
Effectiveness. Opportunistic detection of osteo-
porosis and vertebral fractures from CT data was 
the highest ranking priority, with 70% of patients 
thinking that patients were ‘extremely likely to 
benefit’ from the idea and a further 22% ‘very 
likely to benefit’ (92% score in total).
Data sources
Data sources searched include:
 • NICE Evidence library portal;
 • Systematic reviews via: Cochrane Library;
 • Electronic bibliographic databases: Embase, 
Medline; Tripdatabase; Web of Science;
 • Websites: NICE;
 • Search engines: Google Scholar and Google;
 • Theses and dissertations;
 • Individual companies: Mindways; Optasia 
Medical; ON Diagnostics; Zebra Medical 
were all contacted for supporting research 
literature relevant to their technology.
Grey literature, such as research studies carried out 
by charities and research institutes, reports, com-
mentaries and review papers from government, 
policy bodies and professional organisations, was 
reviewed in support of the academic literature. In 
particular, the Grand Challenge AI for Radiology 
engine for CT products relating to osteoporosis 
and fracture terms was reviewed.
Search strategy
A Boolean search was performed using the opera-
tors AND, OR, NOT in combination with the 
following keywords, index headings and free text: 
Computed tomography; biomechanical com-
puted tomography; computed axial tomography; 
computer assisted tomography; CT; computed 
tomography x-ray absorptiometry; CTXA; finite 
element analysis; FEA; dual energy X-ray absorp-
tiometry; DXA; DEXA; osteoporosis; bone den-
sity; bone mineral density; fracture; screening; 
diagnosis; diagnostic; opportunistic; Mindways; 
Optasia; O.N. Diagnostics; Zebra Medical. 
Truncation techniques using asterisks and wild-
card techniques using question marks were 
employed when free text searching. Additionally, 
reference lists of key relevant primary research, 
systematic reviews and meta- analyses and grey 
literature were examined to identify further stud-
ies. Citation searches of key relevant articles were 
undertaken. Targeted searches for publications 
by key academic researchers were made. Searches 
were limited to the English language.
Osteoporosis, vertebral fragility fractures, 
fracture liaison services and case-finding 
during CT
Osteoporosis and vertebral fragility fractures
Osteoporosis is a disease that causes bones to 
become weak and fragile. It is a major cause of 
disability, loss of quality of life and early death in 
the older population and poses a significant pub-
lic health problem in a globally ageing popula-
tion. The condition is usually asymptomatic until 
a fracture occurs, and patient perception of frac-
ture risk is often underestimated.3 Vertebral fra-
gility fractures occur either spontaneously, as a 
result of normal activities such as lifting or cough-
ing, or from mild trauma. These spinal fractures 
are the most common of all osteoporotic fragility 
fractures, occurring in 25% of men and post-
menopausal women.4 Under-diagnosis is a par-
ticular issue for vertebral fractures as only a 
minority result from a fall and symptoms may be 
attributed by both patients and clinicians to 
another cause.5 Nearly all fractures are associated 
with an increased risk of future fracture, 
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regardless of age, bone mineral density (BMD) 
and fracture location.6 According to the 
International Osteoporosis Foundation (IOF), 
520,000 fragility fractures occurred in 2017 in the 
United Kingdom (UK), costing £4.5 billion. This 
expenditure is set to increase by 30% by 2030 due 
to the ageing population.7–10
Treatment and behavioural interventions for peo-
ple diagnosed with osteoporosis and vertebral 
fractures have been shown to reduce hip and 
other fracture rates by 40–70%.11 A recent com-
prehensive review has found that secondary pre-
vention strategies appear to be better developed 
and more successful than primary prevention 
strategies.12 However, currently less than half of 
patients with a fragility fracture undergo second-
ary osteoporosis screening.13 This is a missed 
opportunity, since the ‘lowest hanging fruit’ in 
secondary prevention of fractures are those peo-
ple presenting to secondary care with a first fragil-
ity fracture. This group includes people found to 
have an incidental vertebral fracture after a CT 
scan, which is the subject of this evidence review.
The role of fracture liaison services
The failure to treat osteoporosis even after knowl-
edge of a fragility fracture is known as the ‘osteopo-
rosis treatment gap’. The percentage of women 
who did not receive treatment after a fracture was 
estimated by the IOF to be 49%.9,10 Despite proven 
efficacy of osteoporosis therapy, simple guidelines 
and multiple simple therapeutic options, treatment 
prescription rates remain sub-optimal.14 Clinical 
care systems have been slow to incorporate second-
ary prevention. The usual care following a low-
trauma fracture (including hip and vertebral) can 
still lack a simple evaluation and/or treatment of the 
osteoporosis that contributed to the fracture.15 A 
multidisciplinary fracture liaison service (FLS) can 
facilitate case identification, investigation and inter-
vention,16 reducing the osteoporosis treatment gap 
and preventing fractures.17–20 Their effectiveness at 
reducing the risk of subsequent fracture is sup-
ported by level 1 evidence from systematic reviews 
with meta-analyses.21,22 Currently, it is unusual for 
FLS to follow up patients whose vertebral fractures 
are identified ‘opportunistically’ during CT scan-
ning for other reasons.
Osteoporosis case-finding during CT
Patients attending hospital for routine CT are a 
group of patients who might be suitable for 
targeted case-finding. The Royal Osteoporosis 
Society and the Royal College of Radiologists 
(UK) have recently overseen education and audit 
initiatives focused on improving the identification 
of osteoporotic vertebral fractures in imaging 
done for other reasons, including CT. Their 
recent audit of UK radiology departments found 
that only 26% of vertebral fractures visualised 
incidentally on CT images were reported accu-
rately, and less than 3% of patients were 
referred onwards for appropriate management 
(see Figure 1).
This review focusses on approved technology sys-
tems and their potential for adoption in health 
services, by which we mean systems that have 
received either FDA approval, ISO 13485 certifi-
cation (in the case of Medical Devices that involve 
a phantom), a European CE mark for diagnosis, 
or are NHS CQC regulated technology services. 
This does not currently include the substantial 
body of research literature investigating the utility 
of direct Hounsfield unit (HU) estimation of 
bone health. In the UK fracture risk assessment is 
generally recommended by the National Institute 
of Health and Care Excellence (NICE) when 
patients have specified co-morbidities – a so-
called targeted case-finding approach.11,23 In the 
case of patients attending hospital for routine CT, 
these patients will often fulfil the NICE criteria 
that recommend a fracture risk assessment due to 
age and co-morbidities. However, CT-attenders 
are not currently targeted for risk assessment. 
Fracture risk assessment using the online FRAX 
tool to input simple questionnaire answers gives a 
person-specific 10-year risk of osteoporotic frac-
ture. A ‘FRAX 10-year risk’ of major osteoporotic 
or hip fracture is therefore the commonest method 
used to identify individuals at high risk of fracture 
in both primary and secondary prevention. The 
electronic output of FRAX in the UK is matched 
with nationally agreed osteoporosis guideline 
thresholds (National Osteoporosis Guideline 
Group: NOGG) that indicate the need for drug 
treatment. However, the current prevalence of 
high-risk patients (by FRAX) attending CT units 
is not known. Enthusiasm to screen all CT attend-
ers with FRAX (or for that matter to investigate 
every single CT image for osteoporosis) must be 
tempered by the clear advice concerning primary 
osteoporosis screening programmes in the UK; 
the National Screening Committee (https://lega-
cyscreening.phe.org.uk/osteoporosis) do not rec-
ommend population screening, citing a lack of 
effectiveness criteria. Nevertheless emerging data 
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from the US on screening with CT bone strength 
analysis are encouraging.24
Diagnosing osteoporosis using DXA
Dual energy X-ray absorptiometry (DXA) 
remains the traditional imaging technique in oste-
oporosis and gold standard for diagnosis. It uses 
an X-ray and detector system to measure the 
mineral content of bone and is especially well 
suited to the average lumbar spine (usually lum-
bar vertebrae 1 and 2 or 1, 2, 3 and 4) as well as 
the proximal femur [femoral neck (FN) and ‘total 
hip’]. The Word Health Organisation (WHO) 
definition of osteoporosis is based on a DXA 
measurement of BMD, deriving from evidence 
showing a clear link between lower BMD and 
increased fracture risk.25 Diagnostic criteria use 
standard deviation (SD) scores of BMD related 
to peak bone mass in healthy young women, with 
osteoporosis being defined as a BMD T score of 
−2.5 or less and low bone mass (osteopenia) as a 
BMD T-score between −1 and −2.5.26 DXA 
BMD values, particularly derived from the FN, 
are a very good indicator of future fracture risk 
and have long been incorporated into modern 
fracture risk estimating tools such as FRAX. 
DXA is subject to the limitations of a planar two-
dimensional (2D) technology to represent a 
three-dimensional (3D) bone, and availability is 
patchy. Another limitation of DXA spine meas-
urements are the inaccuracies in the setting of 
degenerative spinal pathology, and that this meas-
urement is limited only to the lumbar spine. Each 
T-score unit decrease in BMD confers approxi-
mately a doubling of fracture risk. However, most 
osteoporotic fractures occur in individuals who 
do not have an ‘osteoporotic range’ BMD. In 
addition, other risk factors (e.g. age, sex, previous 
fracture) are associated with fracture risk inde-
pendently of BMD.27,28 DXA has a very low radi-
ation dose.
Diagnosing osteoporosis and vertebral 
fractures using CT; technology and services 
overview
Quantitative CT (QCT) is an established 3D 
imaging technique having been used in clinical 
practice since the 1970s. For a clinician seeking a 
diagnosis of osteoporosis in their patient, a CT 
scan is requested far less frequently than DXA 
due to the higher radiation dose with CT. Spine 
QCT measures the true volumetric BMD 
(vBMD) of trabecular bone within vertebrae, 
usually the average of lumbar vertebrae 1 and 2 
(or 1, 2 and 3) with low values being an excellent 
risk marker for prevalent vertebral fracture.29–31 
QCT BMD measurements of the spine do not 
give the same values as DXA (QCT Pro Spine, 
Software Mindways, Austin, TX, USA and 
VirtuOst Spine, O.N. Diagnostics, Berkeley, CA, 
USA). Software can also ‘project’ areal BMD 
(aBMD) of the hip from CT scans, more akin to 
DXA imaging. Like DXA, this areal density (g/
cm2) is measured at the ‘FN’ and ‘total hip’ 
regions (QCT Pro CTXA and VirtuOst Hip) – 
the measurements are directly comparable with 
DXA and can be entered specifically into the 
FRAX online tool to give patient-specific 10-year 
fracture risk and UK treatment thresholds using 
either the ‘Mindways QCT’ drop-down option 
(CTXA) or the ‘T-score’ option (VirtuOst).
Developed as an adjunct to DXA and performed 
on the same machine, ‘vertebral morphometry’ 
images [also called VFA] are used to visualise a 
patient’s entire lateral spine encompassing key 
areas at risk of fracture, from the thoracic to the 
lumbosacral region. Fractures are diagnosed by 
reference to various shape criteria in the lateral 
projection of the wedged, crushed or biconcave-
appearing vertebra. Software technology-based 
services are now emerging that automate or semi-
automate the process of identifying vertebral frac-
tures from CT data, where scans are done for 
other medical reasons and not for the primary 
purpose of osteoporosis assessment. In this 
emerging field, CT scans can be sent to an exter-
nal company (ASPIRE service, Optasia Medical, 
Manchester, UK or AI1 Solutions using Zebra 
Bone Health algorithm, Zebra Medical Vision 
Ltd, Shefayim, Israel). In other scenarios, the 
automatic identification of vertebral fractures is 
integrated with other point of care AI tools visible 
to the radiologist reviewing the original CT scan 
(AI1 Integrations, using the Zebra Bone Health 
Algorithm).
Opportunistic ancillary screening for 
osteoporosis, low bone strength and 
vertebral fractures in CT scans done for 
other indications
Practical aspects of ancillary screening of CT 
data
According to the latest data from NHS England, 
almost 6 million CT scans were performed 
October 2019–October 2020 for patients in 
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England.32 Of these, over 1 million were esti-
mated to include the chest and/or abdomen. If 
opportunistic ancillary screening was performed 
on these CT scans, earlier treatment for those 
with previously undetected osteoporosis might 
have saved and improved lives, and potentially 
saved significant costs to healthcare systems. 
Opportunistic CT-based screening methods have 
the potential to be light-touch (in terms of cost, 
time and inconvenience to stakeholders) and to 
prevent unnecessary hospital visits and further 
irradiation.33
Academic researchers, software companies and 
service providers have realised the potential to 
diagnose osteoporosis and identify vertebral frac-
tures as an ‘added extra’ service applied to CT 
scan images that have already been taken for other 
clinical reasons. A single clinical CT scan consists 
of a batch of hundreds of consecutive 2D slices 
(axial sections) through a person (the number of 
slices depending on the predetermined slice thick-
ness and the amount of the body covered by the 
scan). The software and services for screening for 
osteoporosis and vertebral fractures are not usu-
ally installed on the radiographers’ CT scanning 
personal computer (PC) that drives the CT scan-
ner. Instead the bone analysis software can be 
located either on nearby ‘standalone’ PCs or on 
the radiologists’ analysis terminal [called a picture 
archive and communication system (PACS) diag-
nostic workstation] or even at a totally distant site. 
In the latter case, analysis can be done by techni-
cal staff rather than radiographers, and sometimes 
away from the hospital, as long as the organisation 
providing the service is CQC-approved by the 
NHS. Using computer software to diagnose oste-
oporosis or vertebral fractures can be done any 
time; from minutes to hours after the patient has 
left the CT department, up to many months after 
the original scan. Here, the extra radiation dose is 
zero and the patient may be spared additional 
DXA imaging visits.
Diagnosis and fracture-prediction from QCT 
imaging technologies; landmark studies, 
diagnostic criteria and regulatory aspects
Traditionally, QCT measurements of vBMD 
have been made with specialised software and the 
patient lying on an ergonomic, slim bone calibra-
tion phantom. Phantoms are manufactured with 
materials of known density, usually calcium/
potassium hydroxyapatite and are placed under 
the patient’s lower back and hips in order 
to mitigate for the variability in CT scanners by 
converting CT attenuation (measured in HU) to 
vBMD.34 This is known as synchronous calibra-
tion. Bone density measurements made using 
synchronous calibration have been in clinical 
practice for many years and are usually reported 
by reference to the American College of Radiology 
criteria, where spine BMD values below 80 mg/
cm3 are considered osteoporotic. Age- and sex-
specific reference ranges of spine QCT BMD 
have long been available for adults and diagnostic 
test data are also published.29,30 While age-related 
reference ranges are used to generate Z-scores, to 
avoid confusion, T-scores (the diagnostic WHO 
criteria for DXA) are not generally used. A 
T-score is rather a DXA-specific concept and 
probably best kept linked to that particular pla-
nar, summative imaging method.
In 2014, a suitably designed and powered pro-
spective study of healthy adult men and women 
was published confirming diagnostic accuracy of 
the 80 mg/cm3 threshold (i.e. ‘ACR standardised’ 
phantom-calibrated spine vBMD) in predicting 
(a) vertebral fracture (with complete 5-year fol-
low-up spine imaging for coverage of all vertebral 
fractures occurring in the cohort) and (b) inci-
dent hip fracture (using ICD hospital codes). 
Average spine vBMD (L1 and L2) measured by 
QCT was highly statistically significantly associ-
ated with incident vertebral fracture; age-adjusted 
odds ratio (OR) for vertebral fracture was 3.1 
[95% confidence interval (CI) 2.2–4.7] for every 
one SD lower spine vBMD, giving a typical 
75-year old female or male with baseline vBMD 
of 80 mg/cm3 a 14.6% (11.1, 19.3) predicted 
probability of vertebral fracture.31 A clinical study 
recently found that spine QCT was superior to 
DXA in predicting incident vertebral fracture in 
clinical practice, but caution is needed when eval-
uating the study.35 Data from dedicated healthy 
ageing cohorts that match baseline high-quality 
CT imaging to contemporaneous modern DXA 
methods are needed.
More recent technological advances have opened 
the possibility of calculating the BMD of a patient 
without the phantom being present at the time of 
scan, known as ‘phantom-less’ or ‘asynchronous’ 
approaches. The various methods of achieving 
this are listed in Table 1. The application of this 
nascent technology is highlighted below.
Commercially available methods can also identify 
individuals at high risk of fracture using CT 
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combined with FEA.1,42 Initially introduced 
40 years ago, FEA is a non-destructive computer 
simulation method that estimates the stiffness of a 
structure by dividing it into a number of simple 
parts, termed finite elements, that are connected 
by points termed nodes. Combinations of FEA 
and in vivo bone imaging data have significantly 
improved the estimation of bone mechanical 
behaviour compared with imaging alone.43,44 This 
combined ‘biomechanical CT’ (BCT, VirtuOst 
software, O.N. Diagnostics) approach provides 
non-invasive estimates of the breaking strength of 
the hip and spine. Combining that measurement 
with a CT-based measurement of a DXA-
equivalent hip BMD T-score, BCT provides a 
more comprehensive diagnostic assessment of 
osteoporosis than bone strength or BMD 
alone.36,45–47 In the aforementioned diagnostic 
accuracy study, the age-adjusted BCT OR for inci-
dent vertebral fracture was 4.3 (2.4, 7.6). A 75-year 
old woman whose L1 vertebral strength lies exactly 
on the Fragile Bone Strength threshold for a female 
(4500N) has a predicted probability of vertebral of 
22.2% (18.5, 26.4). The predicted probability of 
vertebral fracture increased more steeply with 
declining L1 Strength than for vBMD.31
From a regulatory perspective, the CQC is the 
UK’s independent regulator of health and social 
care. Their report from March 2020 highlighted a 
range of observations and recommendations.48 
They emphasised the need for good governance 
of clinical, information, technical and human 
aspects of any ML tools in diagnostic services. 
They stated that most suppliers of ML applica-
tions in diagnostics will not need to register with 
CQC, only those that deliver clinical activity 
themselves. These few will need to be regulated 
and assessed by national standards to ensure 
safety and efficacy. The report emphasised that 




•  Patient lies on an ergonomic phantom with materials of known densities (usually 2–5 
rods of different human tissue density equivalents)
•  CT attenuation values of the hip or spine are converted to BMD by reference to the 
known density values (QCT Pro)
•  Hip scans can be adapted to derive areal BMD, suitable for use in FRAX (CTXA)
Phantom-less synchronous 
internal calibration
• No external calibration phantom scanned
•  CT attenuation of adjacent internal tissues (e.g. blood or fat) used to calibrate 
attenuation measurements (VirtuOst)
•  Can be adapted to derive areal BMD, suitable for use in FRAX (VirtuOst Hip, T-score)
Asynchronous external calibration • Phantom scanned regularly.
•  Simple, single-material phantom (Mindways Model 4 phantom, CliniQCT)
•  Hounsfield numbers of bone are then compared with phantom
•  Asynchronous CT of proximal femur can be adapted to derive areal BMD, suitable for 
use in FRAX (CliniQCT CTXA)
Asynchronous external calibration 
with the ACRad phantom
•  Routine calibration using ACRad phantom
•  Direct CT attenuation values (HUs) are used to determine trabecular radiodensity 
without a BMD-specific calibration phantom
•  Does not require specialised software – can be performed on PACS workstation or any 
computer with standard tools used for viewing CT images
ACRad, American College of Radiology; BMD, bone mineral density; CT, computed tomography; CTXA, CT X-ray absorptiometry; FRAX, fracture risk 
assessment tool; HU, Hounsfield units; PACS, picture archive and communication system; QCT, quantitative CT.
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there is need for more assurance about the clinical 
aspects of algorithms in ML and clarity on how 
they can be implemented to ensure high-quality 
clinical care. There is also the need for technology 
suppliers to be clear what their products, solu-
tions and devices do and how they perform, as 
suppliers do not always accurately state whether 
their products use ML, which makes it harder to 
implement devices safely.
Clinical effectiveness of currently available 
tools and services to diagnose osteoporosis, 
low bone strength and vertebral fractures in 
CT scans done for other indications
VirtuOst software, including FE (BCT)
VirtuOst fracture risk assessment service using 
strength-based classifications is referenced by the 
International Society of Clinical Densitometry 
(ISCD) guidelines as suitable for osteoporosis 
identification, fracture risk assessment and ther-
apy monitoring. This technology has been solely 
used in the Mayo Clinic (Rochester, MN, USA) 
for the last 4–5 years, but increased cover and 
reimbursement by Medicare (as an official screen-
ing test for osteoporosis) may lead to wider adop-
tion. The patient’s CT scan is sent to the company 
electronically, the analysis performed by the com-
pany and the results sent back to the ordering 
physician. Regulatory approval anywhere outside 
the US has not yet been applied for.
VirtuOst identifies osteoporosis on the basis of 
BMD, bone strength measurement, or both, at 
the hip and spine using synchronous internal cali-
bration (Table 1).31,49 The results are of diagnos-
tic quality and do not need verification by DXA 
or any other tests. DXA-equivalent areal BMD 
T-scores are obtained for the FN, which can 
therefore be used with FRAX (using the ‘T-score’ 
drop-down box on the FRAX website).50–53 A 
typical report from VirtuOst has areal hip BMD 
(in g/cm2), the associated T-score, plus L1 verte-
bral volumetric BMD in mg/cm3, as well as a 
measure of strength of the hip and vertebra calcu-
lated from 3D FEA. The latter (measured in 
Newtons) is reported by reference to a threshold 
of ‘fragile bone strength’ against age-specific 
expected values. Finally, VirtuOst encompasses a 
VFA covering as much of the spine as is captured 
in an individual’s scan. Each of these components 
of the VirtuOst clinical report has been verified 
independently in large fracture prediction studies 
for hip and spine fractures so that a ‘high risk’ 
individual might achieve that through one or 
more components of their analysis.
The various components of the VirtuOst service 
were validated in nine fracture-outcome studies, 
mostly conducted in the US and Iceland. The 
BCT technique showed BMD scores obtained 
from DXA and CT colonography had a high 
degree of agreement (R2 = 0.84).54 In a cohort of 
136 patients undergoing CT enterography (CTE), 
this technique also demonstrated a high degree of 
sensitivity and specificity for confirming osteopo-
rosis (85.7% and 98.5%, respectively) or osteope-
nia (85.1% and 85.4%, respectively).55 In another 
cohort of 136 women undergoing CT enterogra-
phy, BCT analysis identified osteoporosis (as 
defined by DXA) with 100% specificity in 8 out of 
8 patients, and 98.4% specificity in 126 of 128 
patients (95% CI: 94.5%, 99.6%).56 These data 
are further validated by a US retrospective case-
cohort study of 4000 participants, in which accu-
racy of the BMD T-score as measured by VirtuOst 
analysis was consistent with DXA for all fracture-
risk metrics and both sexes.57 Importantly, the use 
of VirtuOst could be vital in inflammatory bowel 
disease monitoring, where a study of 257 patients 
who underwent CTE and BCT showed 54.5% of 
patients had high/increased fracture risk, of which 
40.3% did not meet any of the Cornerstone 
screening criteria (IBD checklist for monitoring 
and prevention in bone health).58
The prospective diagnostic accuracy of 2D meas-
urements of FN BMD (using QCT) for incident 
hip fracture was established recently using the 
VirtuOst method.31 Average FN aBMD meas-
ured by QCT was highly statistically significantly 
associated with incident hip fracture; age-adjusted 
OR for incident hip fracture was 3.5 (2.5–5.0) for 
every one SD lower FN BMD using QCT, giving 
a 75-year old female with baseline FN BMD 
T-score of −2.5 a predicted probability of hip 
fracture of 21.8% (17.0, 27.5). For men these fig-
ures were slightly higher at OR 3.7 (2.5, 5.6) and 
a 33.4% (23.3, 45.4) probability of hip fracture.
Mindways QCT Pro software (QCT Pro, CliniQCT, 
CTXA hip)
Mindways QCT software calibrates HU measured 
by any CT machine against a bone-density equiva-
lent phantom to give consistent hip and spine bone 
density measurements across devices. There are two 
main products; QCT Pro and CliniQCT; the differ-
ence being that CliniQCT permits opportunistic 
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osteoporosis hip and/or spine assessment from 
abdomino-pelvic scans in any CT scanner that has 
been calibrated with the supplied Model 4 cylinder 
phantom (a small cylinder of uniform material that 
calibrates using the CT beam hardening effect, 
monthly). CliniQCT is the system most relevant to 
this review. BMD measurements can be made from 
a wide range of scans such as abdomen/pelvis/spine 
CT, CT urography and cancer related positron 
emission tomography (PET-CT): the only require-
ments are that the scan covers an appropriate skel-
etal region. This requirement for a local user/analyst 
is one aspect that separates Mindways software 
from the other technologies in this review. There are 
clinical distributors in 12 countries spanning the 
US, Europe and Asia who assist with installation/
training.59
CliniQCT involves the FDA-approved and ISO 
13485-approved ‘asynchronous QCT calibration’ 
method to analyse bone density in CT images 
from any scanner that has been calibrated by the 
Model 4 cylinder phantom. This enables the 
opportunistic use of CT data sets acquired for 
other purposes that did not include a CT calibra-
tion phantom in the patient images; a technical 
obstacle that is also overcome (albeit using a dif-
ferent method) by VirtuOst. Like VirtuOst, 
Mindways’ DXA-equivalent CTXA hip module 
gives areal bone density values (in g/cm2) and 
T-scores that are approved for diagnosis by the 
ISCD, as well as 3D volumetric analysis of BMD 
in the spine (in g/cm3). Phantom scans maintain 
precision and account for drift. Mindways’ CTXA 
data analysed in both a conventional and asyn-
chronous manner confirmed diagnostic accuracy 
with excellent intra-and inter-reader reliability 
and correlation with DXA (r2 = 0.907, 
r2 = 0.82).38,60–63 QCT Pro is different insofar it 
requires a Model 3 flattened, curved phantom to 
be placed under the patient during a dedicated 
hip and or spine scan, plus a separate QA phan-
tom is fitted onto the Model 3 for monthly quality 
scans (or after a CT X-ray tube change).
Mindways software can be run on a standard PC 
and does not require radiology-specific monitors 
or computers. Unlike the other systems in section 
4 of this review, end-users of CliniQCT or QCT 
Pro typically retrieve eligible CT scans into their 
standard PC workstation from any PACS archive 
(at any time), perform the hip/spine analysis on a 
local copy of the CT scans and create a compliant 
clinical report. Alternatively, radiographers may 
decide to send CT scans from the actual CT 
scanning console to the Mindways DICOM server 
(i.e. both ‘push’ and ‘pull’ of CT images is sup-
ported). The software connects directly with any 
hospital PACS infrastructure to facilitate these 
retrieval and send/archive steps. Mindways soft-
ware features a simple graphical user interface 
(GUI), guiding the user through bone analysis, 
creation of the report, printing and, if required, 
exporting the results back to the PACS archive to 
sit alongside the CT slices for all PACS users to 
see; analysis takes 2–3 min. The current Slicepick 
module displays anterior–posterior (AP) and lat-
eral flattened composite spine images and con-
tains basic measurement tools for identifying and 
confirming vertebral fracture by morphometry. 
The QCT Pro measurement of spine BMD (typi-
cally L1–L3 but supported from lower thoracic to 
lower lumbar spine with age and sex-matched ref-
erence data) has FDA approval, as does the 
CTXA method for diagnosing osteoporosis. As 
outlined above, the ACR threshold for spinal oste-
oporosis <80 mg/cm3) is very strongly associated 
with prevalent and incident vertebral fracture.
Even more important than the diagnostic accu-
racy and utility of CTXA measurements of FN 
BMD are their clinical utility when imported into 
the FRAX tool. Thus patient-specific 10-year 
major and hip osteoporotic fracture risk aug-
mented by FN BMD (the gold standard recom-
mended by most national guidelines) can be 
achieved if patients first fill in the FRAX ques-
tionnaire before CT. Indeed, The FRAX tool 
BMD entry has a specific ‘Mindways’ category 
reflecting the acceptance of this way of measuring 
bone density by the ISCD and FRAX; inputting 
CTXA density to FRAX is possible in 66 coun-
tries worldwide at the time of writing. The feasi-
bility of opportunistic screening for osteoporosis 
and vertebral fractures using CliniQCT and 
CTXA with FRAX is currently being tested in the 
PHOENIX study (ISCRTN 14722819, https://
doi.org/10.1186/ISRCTN14722819.)
Optasia medical
Optasia Medical specialises in software powered 
by ML algorithms that support the opportunistic 
case-finding of vertebral fracture patients. The 
Optasia Medical ASPIRE service out-sources the 
reporting of vertebral fractures visualised inciden-
tally on CT, using a high degree of automation, 
combined with oversight from an in-house radi-
ologist to improve the accuracy and efficiency of 
VF reporting. The service is already regulated by 
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the CQC in the UK, and the technology has 
achieved CE-marking. Their technology, developed 
together with academic partners in University of 
Manchester, UK, provides a semi-automated 
quantitative vertebral morphometry devised from 
shape-based statistical modeling.64–69 These are 
used to identify and grade vertebral fractures 
using output measurements including vertebral 
height measurements and ratios and vertebral 
fracture classifications. In a real-world test of the 
software capability on CT scout views, their ear-
lier SpineAnalyzer software, applied to CT lateral 
scout views, provided good-excellent agreement 
with the standard radiologist grading for preva-
lent vertebral fractures, with excellent intra and 
inter-reader reliability (coefficients 0.96–0.98).67
The ASPIRE software is designed to interface to a 
hospital PACS via a virtual machine running on a 
remote network. The software searches PACS for 
any relevant CT scans that include the spine and 
fulfil other criteria for example, patients >50 years 
of age. Identified scans are analysed and the out-
put is reviewed by the radiologist who confirms or 
refutes the diagnosis, following which a report is 
automatically generated and returned to the 
requesting hospital site, the patients GP, and their 
local FLS or bone health team (Figure 2).
Retrospective feasibility studies involved a random 
sample of 1638 scans from five UK NHS Hospitals 
(Croydon, Cambridge, East Lancashire, Oxford 
and Salford).70 Vertebral fractures were identified 
in 237 patients (14.2% ± 2.0). Only 67.7% of 
patients with vertebral fracture identified by the 
service had been found in the original radiology 
report, and only 13.3% of patients had been 
referred for appropriate management. In other fea-
sibility studies of two different NHS sites (n = 7103), 
vertebral fractures were found in 20% of cases, of 
which 34% had been identified in radiology reports 
and 5.2% had been referred for appropriate man-
agement. As a result of the study, 1205 patients 
were referred by the service. These data were used 
to change practice in Croydon, where local physi-
cians implemented a new reporting system to alert 
referrers so that when incidental fractures are found 
on CT they undertake a bone health review accord-
ing to local pathways, ensuring timely assessment 
and treatment as appropriate.71
Zebra Medical Vision
Clinicians are keen to explore ‘point of review’ 
tools that alert the specialist radiologist that the 
CT scan they are reviewing has a prevalent verte-
bral fracture, ‘red flags’ for eventual future verte-
bral fracture or prevalent osteoporosis. Zebra 
Medical Vision (Zebra-Med), focuses on AI in 
medical imaging.72–74 In May 2020, their software 
was FDA approved for opportunistic detection in 
osteoporosis. Zebra-Med analyses chest and 
abdominal CT scans using deep neural network 
technology: a combination of convolutional neu-
ral network and recurrent neural network tech-
nology.75,76 These analyse data from the spine to 
analyse bone density and detect vertebral frac-
tures. The software uses statistical and machine 
learning methods to identify vertebral fractures, 
to measure the minimal L1–L4 vertebral spine 
density or to emulate a lumbar spine DXA 
T-score. The latter DXA emulation approach is 
different to those listed in 4a and 4b and cannot 
be imputed to FRAX at present. The DXA emu-
lation method could be run on 96.5% of CT 
scans in a very large cohort, whereas the method 
approximating L1–L4 minimal trabecular density 
could be run successfully on 62.3% of CT scans.77
Figure 2. Optasia medical service provision (CQC approved).
CQC, Care Quality Commission.
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In addition, Zebra-Med has released another 
bone health application, based on DL, to auto-
matically identify fractures.78 The fracture-identi-
fying component of Zebra’s AI1 software could 
be run successfully on 84.3% of CT scans in the 
aforementioned cohort. The software extracts a 
virtual sagittal section visualising the spinal mid-
plane and identifies VFs using ML algorithms. It 
outputs the probability that the volume contains a 
VF, and a heat map indicating the probable loca-
tion of the VF in the sagittal image. In a single-
site ‘real world’ clinical implementation study 
involving thoracic CT scans from 1696 patients 
with a VF prevalence of 24%, the system achieved 
a sensitivity of 54%, specificity of 92% and accu-
racy of 83%. The radiologist or other clinician is 
tasked with confirming whether the algorithmic 
output is correct and, if so, to grade the fracture.79 
From 48,227 individuals (51.8% women) age 
50–90, the Zebra-Med algorithms applied 
together showed non-inferiority to basic FRAX in 
assessing 5-year fracture risk, and slightly better 
sensitivity and positive predictive value (+2.4%, 
+0.7% respectively). A shortcoming is that the 
study used only the most basic FRAX from charts 
rather than the online calculator to derive FRAX 
estimates; this is therefore based on the number 
of risk factors rather than the actual individually 
weighted risk factors.
In a different study using chest and abdominal 
CT scans from 1000 patients, sensitivity, specific-
ity and accuracy were 84%, 73% and 82% respec-
tively.80 Simulated T-scores for 1693 CT studies 
compared with DXA showed few false positives 
(n = 92) relative to true positives (n = 1444) but 
more false negatives (n = 212) compared with true 
negatives (n = 245.) Clinical applications have 
been implemented in Europe and the US and, in 
partnership with tele-diagnostic company Tererad 
Tech, have expanded Zebra’s cloud-based DL 
analytics engine to more than 20 countries and 
150 hospitals and healthcare organisations in 
India, Africa and Asia.
CT measurements of Hounsfield units
While there are many research studies evaluating 
CT HU for osteoporosis screening applications, 
the HU thresholds for consistent application 
across devices vary both with device and with pro-
tocol so it is not considered feasible to undertake 
a calibration exercise for each combination of 
device and protocol, meaning that such methods 
have not achieved clinical adoption and are 
unlikely to ever fulfil ‘approved technology’ status 
(see above for definitions). They are not dealt 
with further in this review.
Cost-effectiveness, futility and  
acceptability studies
For the implementation of opportunistic screen-
ing of CT for osteoporosis in a healthcare setting, 
understanding of its cost-effectiveness is vital, 
especially given the amount of work generated 
downstream for FLS and prescribers. It is also 
important to know in which patients screening 
would be futile. This is particularly true for 
opportunistic evaluation of CT; many routinely 
acquired CT scans are for patients with cancer or 
cancer-monitoring in whom mortality is higher 
than the general public. Indeed, the ancillary 
finding of a vertebral fracture in CT reduces sur-
vival markedly; from around 60% 4-year survival 
to about 30% 4-year survival (in adults 75 years 
or older undergoing chest CT)81. Here, there is a 
large research gap.
There have been only a small number of cost-
effectiveness studies published. In a state-transi-
tion simulation study of a hypothetical cohort of 
1 million post-menopausal women age >55 years, 
a screening programme of combined DXA and 
QCT performed at age 55 years with subsequent 
QCT every 5 years, was found to be most cost 
effective [$2000 per quality-adjusted life year 
(QALY)].24 With this strategy, there was a 12.8% 
lifetime hip fracture risk, compared with 18.7% 
with no screening and 15.8% with DXA alone. 
Favourable outcomes were also seen for wrist and 
vertebral fractures. However, this study is specific 
to a US Healthcare system model, and focused 
mostly on White American women. In an earlier, 
separate analysis, Viceconti calculated that BCT 
could be cost effective in the UK at $14,656 per 
QALY,47 if offered at a fee of $100 per patient in 
addition to payment for a dedicated CT examina-
tion.82 Neither of these studies consider an oppor-
tunistic approach, and do not study men.
A more recent analysis focussed on a one-time 
ancillary BCT offered only to patients already 
undergoing abdominal CT, and who had not had 
a recent DXA.83 Researchers used a one-time 
biomechanical CT test (VirtuOst) to assess the 
accuracy and cost-effectiveness of this strategy in 
male and female patients aged >65 years in a 
hypothetical cohort of 1000 patients who under-
went either this BCT approach or usual care 
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using DXA or no screening. The BCT approach 
proved more cost-effective and clinically benefi-
cial. Using the biomechanical CT strategy, 90% 
of women were screened and 21% tested positive 
for osteoporosis. Using DXA, 37.4% were 
screened and 12.5% tested positive for osteopo-
rosis. For women, when using the no-screening 
model as a reference point, biomechanical CT 
prevented 5.5 hip fractures while DXA prevented 
2.4 hip fractures. For men, biomechanical CT 
prevented 2 hip fractures and DXA prevented 0.2 
hip fractures. When screening was restricted to 
patients at a 2-fold higher risk for hip fracture, 
prevented hip fractures also increased 2-fold with 
biomechanical CT, with a proportional increase 
in cost savings. These studies show promising 
results; however, more data specific to different 
healthcare systems and populations are crucial in 
the integration of these technologies into the 
healthcare setting. Finally, there is no data pub-
lished describing patient attitudes to being offered 
‘opportunistic’ screening. While there are general 
support from the osteoporosis patient commu-
nity, work is needed to identify concerns and 
expectations among CT attenders.
Barriers for implementation of novel 
osteoporosis screening technologies and 
possible solutions
Non-adoption, adoption or abandonment of 
osteoporosis screening technologies and the 
challenges to scale-up, spread and sustain 
such technologies in healthcare organisations 
and systems
It takes on average 17 years to incorporate research 
discoveries into the practice of healthcare provid-
ers.84 A thorough review of this topic is beyond the 
scope of this rapid evidence review; therefore, we 
include a few highlights and key themes relevant 
to embedding existing technologies into the NHS. 
Greenhalgh et  al. developed an evidence-based 
framework for studying the non-adoption, adop-
tion or abandonment of technologies and the chal-
lenges to scale-up, spread, and sustain such 
technologies in healthcare organisations and sys-
tems (abbreviated NASSS).85,86 The NASSS 
framework includes seven domains: the condition/
illness, the technology, the value proposition, the 
adopters, the organisation(s), the wider context 
and changes over time. Each domain can be rated 
Table 2. The 10 NASSS principles applied to opportunistic analysis for osteoporosis using clinical CT 
(Greenhalgh).90
1.  Strengthen program leadership across academic and commercial research, NHS radiology, FLS, IT, 
metabolic bone, patient and public involvement, NHS procurement and management departments
2.  Develop a vision for National opportunistic screening of CT scans for osteoporosis and fractures
3.  Nurture key relationships between software developers, designers, vendors, image analysis providers, 
NHS X, CCGs, NIHR, RCR, Society of Radiographers, image exchange portal, ROS, ISCD and other 
essential stakeholders
4.  Develop champions through the national Academy initiatives and encourage them to problem solve 
local problems creatively
5.  Make resources available via the academy and other funding organisations for creative individuals/
teams to use for generating solutions to local challenges to implement image analysis
6.  Capture data on progress and feedback to leadership, teams and individuals
7.  Acknowledge and address concerns of frontline NHS staff from idea to implementation
8.  Work with intended users to co-design practice-ready imaging technologies and FLS integration
9.  Control scope of the project, for example, concentrating initially on moderate- severe vertebral 
fractures
10.  Address regulatory and policy barriers via CE marking, ISO certification, FDA approval, ISCD
CCG, clinical commissioning groups; CT, computed tomography; FDA, United States Food and Drug Administration; 
FLS, fracture liaison service; ISCD, International Society for Clinical Densitometry; ISO, International Organization for 
Standardization; IT, information technology; NHS, National Health Service; NIHR, National Institute of Health Research; 
RCR, Royal College of Radiologists; ROS, Royal Osteoporosis Society.
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from simple to complex, with more complex pro-
jects being associated with higher failure rates. 
The NASSS framework can be applied to tech-
nologies in health and care either prospectively, to 
guide design and implementation, or retrospec-
tively, to learn from failure. A diverse range of 
technology-supported programmes has been 
tested using this framework. Failure is often linked 
with complexity across multiple NASSS domains, 
and 10 principles have been highlighted to help 
manage and minimise this complexity. Table 2 
shows the application of these principles to the 
current osteoporosis challenge. Opportunistic 
screening for osteoporosis and vertebral fractures 
in CT comes up against the four well-recognised 
barriers to implementation of technology in the 
NHS. First, against poor communication and 
connectivity, which slows innovation across indi-
viduals and organisations due to the fragmented 
structure of UK health services. Second, against 
lack of evaluation by NICE of the complex new 
technology. Third, against a lack of funding to 
take technologies forward for implementation at 
scale, even after successful pilots. Finally, even 
well designed innovations require system changes 
that the NHS is simply unable to afford the time, 
money and staff to implement, despite clear evi-
dence that these changes would bring major ben-
efits in the long run. An Institute of Public Policy 
Research report concluded that whilst barriers can 
vary between different innovations, a number of 
common problems exist across most innovations, 
namely: complexity, culture and money.87 Several 
organisations and reports have highlighted chal-
lenges in implementing novel technologies in the 
NHS and provided some guidance on how these 
can be overcome. These include The Nuffield 
Trust, The Kings Fund and the Institute for 
Public Policy Research.88,89
Several initiatives and organisations exist that try 
to improve the process. The NHS Accelerated 
Access Collaboration, NHS Innovation Accelerator 
and its associated programmes support fast-track 
of innovations from idea to adoption and spread; 
evaluation of this organisation has shown effective-
ness in scale-up and spread of innovations.87,91–96 
In April 2020, in the NHS Long Term Plan, a 
MedTech Funding Mandate was introduced as 
part of the wider strategy to accelerate the uptake 
of NICE-approved cost-saving MedTech products 
in the NHS.97–99 Evidence shows that nationally 
managed schemes resulted in a more rapid and 
complete uptake compared with devices that were 
not part of a national programme.100 In February 
2019, NHSX was established as a government unit 
that is responsible for setting consistent national 
policy and developing best practice for technology, 
digital services and data throughout the NHS.101,102 
NHSX is actively looking at screening programmes 
for high-risk populations, but it is currently unclear 
whether or how this unit’s work would be relevant 
to this technology’s implementation.
How osteoporosis screening from clinical 
CT could follow a successful pathfinding CT 
software technology solution into routine NHS 
practice: HeartFlow FFRCT
An example of NHS software technology adop-
tion is HeartFlow FFRCT – a technology that 
was recommended by NICE under its medical 
technologies guidance work stream (MTAG).103 
HeartFlowFFR is used to estimate fractional flow 
reserve from CT coronary angiography, and may 
avoid the need for invasive coronary angiography 
in patients with stable, recent onset chest pain. 
Draft recommendations based on all the evidence 
presented in the support of the technology were 
given, considering key clinical outcomes. NICE 
considered a total of over 69 studies comprising 
diagnostic accuracy, clinical effectiveness and 
cost-evidence. It is notable that this represents far 
more evidence than is available for the osteoporo-
sis technologies. Whilst HeartFlowFFR was 
selected by the MTAG committee in December 
2014, the final guidance was not published until 
February 2017 (27 months) demonstrating the 
long timescales often involved.
Discussion: areas for further research and 
development
Ancillary screening of CT data for osteoporosis 
and vertebral fractures is well supported by 
numerous academic papers focussed on software 
development and successful use in clinical prac-
tice. Various tools can now provide a rapid and 
reproducible screening method for osteoporosis 
and previously unidentified fractures. However, 
there are areas where further research is needed in 
order to address evidence gaps. It is currently 
unclear which patient groups should be included 
in opportunistic screening. It could be used exclu-
sively in older adults, or also include other high-
risk groups. A large proportion of routine CT 
attenders have specific co-morbidities, such as 
cancer, in comparison with the general popula-
tion. Thus, while they have a higher unmet osteo-
porosis burden, the effects of screening, treatment 
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and survival in these attenders needs to be under-
stood in order to ascertain its clinical impact and 
cost-effectiveness.
It is yet to be determined how opportunistic CT 
imaging could be clinically integrated with cur-
rent diagnostic methods. Determining whether it 
would be used in addition to, or instead of DXA, 
and for screening and/or definitive diagnosis, 
remains to be established. Further data will be 
required on which site(s) should be primarily 
used in opportunistic CT screening; for example, 
regions within the lumbar spine or hip and, if so, 
which sub-regions. The additional value of meas-
uring hip and spine bone strength with CT FEA 
(to diagnose and treat patients on the basis of 
FBS) over simpler QCT methods needs to be 
quantitated. There are also no head-to-head stud-
ies providing comparative data that assess whether 
technologies that detect fracture are more effec-
tive than those assessing bone density/ bone 
strength, or comparing these technologies with 
any other methods of opportunistic screening.
Further understanding of the technology itself 
will be key to its widespread implementation. 
Each of the different calibration techniques has 
advantages and pitfalls; and additional research is 
necessary to characterise the sources of variation 
between scans using each calibration technique. 
In addition, the exact effect of IV contrast on the 
accuracy of the data is not yet known.
There are several service delivery issues. Should the 
services be standalone outside the NHS, embedded 
as ‘point of care’ or near ‘point of care’ tools and 
when should CT data be ‘sent’ for screening? A key 
emerging issue is the ability for healthcare providers 
to manage the higher workload resulting from 
increased case-finding. FLS and other healthcare 
providers could potentially be required to consult, 
administer treatment, follow up and monitor vastly 
increased numbers of affected patients. Local sys-
tems for service delivery would need to be estab-
lished. These include logistics of how relevant 
diagnostic images would be stored, transmitted to 
healthcare providers (HCPs) and FLS teams, and 
how follow-up measurements, for instance, with 
DXA, would be comparable for the purposes of 
monitoring or drug-cessation.
Conclusion
Osteoporosis imposes a significant public health 
impact, as well as cost burden, and is increasing in 
prevalence. It remains under-diagnosed and 
under-treated. There is evidence from the litera-
ture to support multiple technologies using oppor-
tunistic screening of CT scans done for other 
indications, which could increase the rates of diag-
nosis, and therefore treatment to prevent frac-
tures. There are still areas where further research 
is needed. However several barriers remain to the 
implementation of technologies into healthcare 
systems; encompassing problems with culture, 
complexity and funding. With further research 
and the use of new and existing initiatives, there 
may be opportunities for the implementation of 
these technologies into clinical practice.
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